I like these gappers. All are earnings beats except GALE, which got patent acceptance for its breast cancer drug, protecting its method until 2028 in Australia. NMBL is an IPO which beat their first EPS/Revs estimate, so good job to them!
- OVTI
- MELI
- AL
- YOKU
- NMBL
- WUBA
- REGI
- GALE
- DDD
Submitted February 28, 2014 at 09:21AM by greenbartrading http://ift.tt/1cfkXR6
No comments:
Post a Comment